| scholarly article | Q13442814 |
| P50 | author | Rachel Rau | Q55283665 |
| P2093 | author name string | Patrick Brown | |
| Soheil Meshinchi | |||
| Donald Small | |||
| Todd A Alonzo | |||
| Gary Dahl | |||
| Myron Chang | |||
| Norman Lacayo | |||
| Robert J Arceci | |||
| Emily McIntyre | |||
| P2860 | cites work | Nucleolar protein B23 has molecular chaperone activities | Q22009438 |
| Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication | Q24290438 | ||
| Nucleophosmin regulates the stability and transcriptional activity of p53 | Q24300176 | ||
| Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype | Q27824827 | ||
| Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype | Q27824842 | ||
| Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations | Q27824843 | ||
| Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype | Q27824844 | ||
| Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). | Q27824861 | ||
| Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma | Q28250347 | ||
| The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties | Q28283156 | ||
| ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway | Q28506702 | ||
| Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization | Q28572689 | ||
| Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. | Q30444746 | ||
| Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia | Q31774863 | ||
| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite | Q34517403 | ||
| DNA repair during organogenesis | Q34994569 | ||
| Clinical implications of FLT3 mutations in pediatric AML. | Q35848876 | ||
| Environmental genotoxicants/carcinogens and childhood cancer: bridgeable gaps in scientific knowledge | Q36531134 | ||
| Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance | Q38321981 | ||
| Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes | Q38338957 | ||
| Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. | Q44189526 | ||
| Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. | Q44401465 | ||
| Hazard Rate Models with Covariates | Q52776795 | ||
| FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. | Q54008419 | ||
| Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. | Q54613492 | ||
| Detection of normal and chimeric nucleophosmin in human cells | Q61411738 | ||
| Preribosomal ribonucleoprotein particles are a major component of a nucleolar matrix fraction | Q70026444 | ||
| Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) | Q78290356 | ||
| Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12 | Q79412055 | ||
| Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations | Q79954785 | ||
| Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML | Q81600809 | ||
| Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype | Q81712971 | ||
| Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia | Q81919725 | ||
| Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution | Q82843896 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 979-985 | |
| P577 | publication date | 2007-04-17 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | The incidence and clinical significance of nucleophosmin mutations in childhood AML. | |
| P478 | volume | 110 |
| Q39274623 | A surrogate marker to detect nucleophosnim (NPM1) gene mutations in the cytoplasm of acute myeloid leukemia (AML) blast cells in 30 adult Iraqi patients |
| Q41636372 | Accurate Medicine: Indirect Targeting of NPM1-Mutated AML. |
| Q38479156 | Acute myeloid leukemia in infants: biology and treatment |
| Q47102086 | Application of the AMLprofiler Diagnostic Microarray in the South African Setting. |
| Q34764504 | Biology, risk stratification, and therapy of pediatric acute leukemias: an update |
| Q35857599 | Cancer stem cells: impact, heterogeneity, and uncertainty |
| Q27005960 | Childhood acute myeloid leukaemia |
| Q38068816 | Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia |
| Q36053792 | Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia |
| Q36290737 | Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia |
| Q35909648 | Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. |
| Q88384410 | Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate-risk cytogenetics |
| Q35430146 | Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group |
| Q37185272 | Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. |
| Q54720362 | Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia. |
| Q82668142 | Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML |
| Q36805474 | Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group |
| Q47136441 | Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia |
| Q85049016 | Genetic alterations in children and adolescents with acute myeloid leukaemia |
| Q44546687 | Genetic changes including gene copy number alterations and their relation to prognosis in childhood acute myeloid leukemia. |
| Q33555627 | Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia |
| Q54491280 | Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. |
| Q48284209 | Genomics in childhood acute myeloid leukemia comes of age. |
| Q37125803 | High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group |
| Q34154213 | High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia |
| Q26992280 | How I treat pediatric acute myeloid leukemia |
| Q37532145 | Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature |
| Q33327492 | Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations |
| Q40100589 | KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia |
| Q35046171 | Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group |
| Q36513773 | Measurements of treatment response in childhood acute leukemia |
| Q36508284 | Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? |
| Q42832529 | Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help. |
| Q44599346 | Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population |
| Q40519542 | NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value |
| Q37599556 | NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease |
| Q34755985 | Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. |
| Q37833502 | Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. |
| Q50951275 | Nucleophosmin mutation in de-novo acute myeloid leukemia. |
| Q92503784 | Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia |
| Q80826362 | Nucleophosmin mutations in acute myeloid leukemia in children |
| Q40781300 | Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols |
| Q38196743 | Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia |
| Q36739522 | Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). |
| Q46370523 | Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. |
| Q24602856 | Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group |
| Q34052581 | Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. |
| Q33754603 | Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. |
| Q57795857 | Prognostic impact of low allelic ratio ITD and mutation in acute myeloid leukemia |
| Q39450821 | Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia |
| Q30248904 | Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies |
| Q34316768 | Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia |
| Q48188218 | Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group. |
| Q47805959 | Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia |
| Q36981845 | Progress of minimal residual disease studies in childhood acute leukemia |
| Q36734631 | Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia. |
| Q37260361 | Recent advances in management of acute myeloid leukemia (AML). |
| Q36194222 | Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. |
| Q37598941 | Role of nucleophosmin in acute myeloid leukemia. |
| Q47579484 | Single-cell whole exome and targeted sequencing in NPM1/FLT3 positive pediatric acute myeloid leukemia. |
| Q44140110 | Successful use of second cord blood transplantation to achieve long-term remission in cord blood donor cell-derived AML harboring a FLT3-ITD and an NPM1 mutation |
| Q37671778 | The challenge of risk stratification in acute myeloid leukemia with normal karyotype |
| Q41704381 | The frequency of NPM1 mutations in childhood acute myeloid leukemia |
| Q57461728 | The pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult AML |
| Q45012427 | The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group. |
| Q38065068 | The role of HOX genes in normal hematopoiesis and acute leukemia. |
| Q90029220 | Using genomics to define pediatric blood cancers and inform practice |
| Q33872395 | miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group |
Search more.